Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson
Annals of Clinical and Translational Neurology · Wiley · 2026-11-12 · DOI: 10.1002/acn3.70395

Аннотация

Annals of Clinical and Translational Neurology, Volume 13, Issue 11, Page 2278-2288, November 2026.

Читать у издателя →

Похожие статьи